Option chain shows key data for Lixte Biotechnology's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lixte Biotechnology.

Lixte Biotechnology (NASDAQ:LIXT) Stock, Option Chain

Lixte Biotech Hldgs

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

VFCorp.Shutterstock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMKR

AREB

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DBGI

EVOK

FFIV

GRDI

HLIT

HRYU

IMRN

IVDA

LIXT

LTBR

QUBT

SHPH

TMDX

VEEA

Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket

Tysons,,Usa,-,January,26,,2018:,Nordstrom,Store,Sign,Entrance

AEMD

AMBA

ARBB

BSLK

ENSC

IDAI

JBDI

MGNI

NCNO

PITA

STEC

SVRE

TANH

VNET

WALD

Why Nordstrom Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Wall Street US stocks

Earnings

Equities

Eurozone

Commodities

Intraday Update

AAMC

ADXN

CSCI

SCSC

VOXX

US Stocks Mixed; ScanSource Reports Weak Q4 Results

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings, Inc. - Warrants

Press Releases

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Biotech

Events

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

LIXTE Biotechnology Provides Update On Recent Activities and Developments

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

"Stocks Key Trendlines: PRSO, PFIE, SHPH, BKYI, LIXT on the Verge of Breakthroughs"

BKYI

LIXTW

PFIE

PRSO

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

180 Life Sciences

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Genprex

GRI Bio

GT Biopharma

Lixte Biotechnology

Mustang Bio

Moleculin Biotech

Onconetix

Organovo Holdings

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Portage Biotech

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Soligenix

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Tharimmune

Theriva Biologics

T2 Biosystems

Vincerx Pharma

Lixte Biotech Holdings

Comments

Lixte Biotechnology

Lixte Biotechnology (LIXT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga